| Parent Drug Name | Name of Impurity | Catalogue No. | |
|---|---|---|---|
| Baricitinib | Baricitinib Impurity 1 | VL3190001 | View |
| Baricitinib | Baricitinib Impurity 2 | VL3190002 | View |
| Baricitinib / Ruxolitinib | Baricitinib Impurity 3 | VL3190003 | View CAS 1187595-89-6 |
| Baricitinib | Baricitinib Impurity 4 | VL3190004 | View |
| Baricitinib | Baricitinib Impurity 5 | VL3190005 | View |
| Catalogue No. | VL3190003 |
| CAS No. | 1187595-89-6 |
| Molecular Formula | C17H19N7O3S |
| Molecular Weight | 401.45 |
| Parent drug | Baricitinib / Ruxolitinib |
| IUPAC Name | 1-(ethylsulfonyl)-3-[4-[7-(hydroxymethyl)-7H-pyrrolo[2, 3-d]pyrimidin-4-yl]-1H-pyrazol-1-yl]-3-Azetidineacetonitrile |
| Synonyms | Ruxolitinib Hydroxy Impurity |
| References | “Sci-Hub, Baricitinib: First Global Approval, 10.1007/S40265-017-0723-3.” Hkvisa.net, 2017, sci-hub.hkvisa.net/10.1007/s40265-017-0723-3. |
| Status | In-stock |
| ListName | Baricitinib Impurity 3 |
| Exclusively Supplied by Veeprho | Exclusively Supplied by Veeprho |
"*" indicates required fields
